Inactive Instrument

Oxford Immunotec Global PLC

Equities

OXFD

GB00BGFBB958

Oxford Immunotec Global Appoints Patrick J. Balthrop to its Board of Directors

February 02, 2016 at 03:30 am IST

Oxford Immunotec Global PLC announced the appointment of Patrick J. Balthrop, Sr. to its Board of Directors. Pat has been a leader in the medical technology field for over three decades and will be a great addition to its Board. Most recently, Mr. Balthrop served as President and CEO of Luminex Corporation from 2004 to 2014, during which time the company's revenues grew eightfold.

Latest news about Oxford Immunotec Global PLC

Oxford Immunotec Announces Use of T-SPOT®Discovery SARS-CoV-2 Kit	29/21/29	CI
Oxford Immunotec Global PLC will Change its Name to Oxford Immunotec Global Limited	09/21/09	CI
Oxford Immunotec Global PLC Announces Board Changes	09/21/09	CI
Oxford Immunotec Global PLC(NasdaqGM:OXFD) dropped from S&P Global BMI Index	08/21/08	CI
Oxford Immunotec Global PLC(NasdaqGM:OXFD) dropped from NASDAQ Composite Index	08/21/08	CI
PerkinElmer (UK) Holdings Limited completed the acquisition of Oxford Immunotec Global PLC.	08/21/08	CI
Oxford Immunotec Global PLC's Equity Buyback announced on January 7, 2019, has expired.	08/21/08	CI
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection	05/21/05	CI
Oxford Immunotec Global : Plans to Market T Cell Immune Response Measurement Kit to COVID-19 in South Korea	09/21/09	MT
Oxford Immunotec Global PLC Enters into A Memorandum of Understanding Green Cross Medical Science Corp. to Market the T-SPOT Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea	08/21/08	CI
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-Cov-2 Kit and Include New Panel to Detect T Cells Reactive to Endemic Coronaviruses	04/21/04	CI
Oxford Immunotec Global : Teams With Valneva on COVID-19 Vaccine Candidate Testing	14/21/14	MT
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study	13/21/13	CI
Sector Update: Health Care Stocks Add to Early Rise, Supported by Biotech Companies	08/21/08	MT
Sector Update: Modest Advance for Health Care Stocks Despite Larger Gains for Biotechnology Sector	08/21/08	MT
OXFORD IMMUNOTEC GLOBAL : JP Morgan Downgrades Oxford Immunotec Global to Neutral From Overweight, Keeps $22 Price Target	07/21/07	MT
OXFORD IMMUNOTEC GLOBAL : Piper Sandler Downgrades Oxford Immunotec Global to Neutral from Overweight, Adjusts Price Target to $22 from $24	07/21/07	MT
DJ Industrial : Wall Street Sees Upbeat Open as US Congress Certifies Biden's Win After Capitol Chaos	07/21/07	MT
PerkinElmer : to Acquire Oxford Immunotec for $591 Million	07/21/07	MT
PerkinElmer (UK) Holdings Limited entered into an agreement to acquire Oxford Immunotec Global PLC (NasdaqGM:OXFD for approximately $560 million.	07/21/07	CI
Transcript : Oxford Immunotec Global PLC - Analyst/Investor Day	17/20/17
Oxford Immunotec Global : Gets Approval for T-Cell Select Reagent Kit for Tuberculosis Testing in South Korea	10/20/10	MT
Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit	10/20/10	CI
Oxford Immunotec Global : Signs Exclusive Distributor Agreement with Riken Genesis for SARS-CoV-2 Kit	02/20/02	MT
Oxford Immunotec Global PLC Signs Exclusive Distributor Agreement with Riken Genesis, to Market the T-SPOT Discovery SARS-CoV-2 Kit for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection in Japan	02/20/02	CI

Chart Oxford Immunotec Global PLC

Duration

Period

More charts

Company Profile

Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.

Sector

More about the company